David T Teachey

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. pmc New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome
    David T Teachey
    Division of Pediatric Hematology, Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
    Curr Opin Pediatr 24:1-8. 2012
  2. ncbi Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
    David T Teachey
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 121:5154-7. 2013
  3. pmc Targeting Notch signaling in autoimmune and lymphoproliferative disease
    David T Teachey
    Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104, USA
    Blood 111:705-14. 2008
  4. pmc Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Divisions of Oncology and Hematology, Children s Hospital of Philadelphia, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Blood 108:1965-71. 2006
  5. pmc mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 112:2020-3. 2008
  6. pmc Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
    Valerie I Brown
    Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA, 19104, USA
    Immunol Res 42:84-105. 2008
  7. pmc Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
    David T Teachey
    Division of Paediatric Hematology, Children s Hospital of Philadelphia, 3615 Civic Centre Boulevard, Philadelphia, PA 19104, USA
    Br J Haematol 145:569-80. 2009
  8. pmc Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling
    David M Barrett
    Department of Pediatrics, Division of Oncology, Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Blood 118:e112-7. 2011
  9. pmc Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
    Shannon L Maude
    Division of Oncology, The Children s Hospital of Philadelphia, PA, USA
    Blood 120:3510-8. 2012
  10. doi Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study
    Alix E Seif
    Division of Hematology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 115:2142-5. 2010

Collaborators

Detail Information

Publications25

  1. pmc New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome
    David T Teachey
    Division of Pediatric Hematology, Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
    Curr Opin Pediatr 24:1-8. 2012
    ..Clinical manifestations include lymphadenopathy, splenomegaly, and autoimmune cytopenias. A number of new insights have improved the understanding of the genetics and biology of ALPS. These will be discussed in this review...
  2. ncbi Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
    David T Teachey
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 121:5154-7. 2013
    ..This trial was registered at www.clinicaltrials.gov as #NCT00103285. ..
  3. pmc Targeting Notch signaling in autoimmune and lymphoproliferative disease
    David T Teachey
    Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104, USA
    Blood 111:705-14. 2008
    ..Inhibiting the Notch signaling pathway may thus present an effective, novel, and well-tolerated treatment for autoimmune and lymphoproliferative diseases...
  4. pmc Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Divisions of Oncology and Hematology, Children s Hospital of Philadelphia, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Blood 108:1965-71. 2006
    ..We conclude that rapamycin is an effective treatment for murine ALPS and should be explored as treatment for affected humans...
  5. pmc mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 112:2020-3. 2008
    ..We found methotrexate and MTIs are an effective and potentially synergistic combination in ALL...
  6. pmc Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
    Valerie I Brown
    Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA, 19104, USA
    Immunol Res 42:84-105. 2008
    ....
  7. pmc Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
    David T Teachey
    Division of Paediatric Hematology, Children s Hospital of Philadelphia, 3615 Civic Centre Boulevard, Philadelphia, PA 19104, USA
    Br J Haematol 145:569-80. 2009
    ..This review describes the rationale for using mTOR inhibitors in a variety of haematological diseases with a focus on their use in leukaemia...
  8. pmc Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling
    David M Barrett
    Department of Pediatrics, Division of Oncology, Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Blood 118:e112-7. 2011
    ....
  9. pmc Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
    Shannon L Maude
    Division of Oncology, The Children s Hospital of Philadelphia, PA, USA
    Blood 120:3510-8. 2012
    ....
  10. doi Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study
    Alix E Seif
    Division of Hematology, Department of Pediatrics, Children s Hospital of Philadelphia, PA 19104, USA
    Blood 115:2142-5. 2010
    ..This is the largest published series describing children with ES and documents a high rate of ALPS among pediatric ES patients. These data suggest that children with ES should be screened for ALPS with DNTs...
  11. pmc Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    Stephan A Grupp
    Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 368:1509-18. 2013
    ..The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL...
  12. ncbi Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies
    David Barrett
    Department of Pediatrics, Division of Oncology, Childrens Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Paediatr Drugs 14:299-316. 2012
    ....
  13. doi Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant
    David T Teachey
    Division of Hematology, Children s Hospital of Philadelphia, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 53:1114-6. 2009
    ..Altering the immunosuppressive regimen to modify T-cell dysregulation may be beneficial for patients who develop post-transplant autoimmune disease and allow continued preservation of allograft...
  14. ncbi Managing cytokine release syndrome associated with novel T cell-engaging therapies
    Shannon L Maude
    From the Division of Pediatric Oncology, and Department of Pathology, Children s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
    Cancer J 20:119-22. 2014
    ..One approach we have developed targets IL-6, a prominent cytokine in CRS, using the IL-6R antagonist tocilizumab. We will review the pathophysiology and management options for CRS associated with T cell-engaging therapies. ..
  15. doi Diagnosis and management of autoimmune cytopenias in childhood
    David T Teachey
    Pediatric Hematology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, 3501 Civic Center Boulevard, Philadelphia, PA 19104, USA Electronic address
    Pediatr Clin North Am 60:1489-511. 2013
    ....
  16. pmc The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 107:1149-55. 2006
    ..We conclude that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy...
  17. pmc Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens
    Deepakbabu Chellapandian
    Department of Pediatrics, Einstein Medical Center, Philadelphia, PA, USA
    Br J Haematol 162:376-82. 2013
    ..These data support the incorporation of rituximab into future prospective clinical trials for patients with EBV-HLH...
  18. pmc Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Children s Hospital of Philadelphia, University of Pennsylvania, 19104, USA
    Br J Haematol 148:205-16. 2010
    ..This review describes the clinical and laboratory manifestations found in ALPS patients, as well as the molecular basis for the disease and new advances in treatment...
  19. pmc Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome
    David T Teachey
    Pediatric Hematology and Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia PA 19104, USA
    Br J Haematol 145:101-6. 2009
    ..Based on these significant responses, we recommend that sirolimus be considered as second-line therapy for patients with steroid-refractory disease...
  20. ncbi Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood
    Benjamin R Oshrine
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Electronic address
    Biol Blood Marrow Transplant 19:1581-9. 2013
    ..Efforts to enhance IR after partial TCD-PBSC transplantation, such as selective αβ T cell depletion, hold promise for further improvement of this transplantation approach. ..
  21. ncbi Toxicity management for patients receiving novel T-cell engaging therapies
    David M Barrett
    Division of Pediatric Oncology, Children s Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine, Pennsylvania, USA
    Curr Opin Pediatr 26:43-9. 2014
    ..These therapies produce nonphysiologic T-cell activation, which is the hallmark of these new, highly active treatments...
  22. pmc Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 18:6058-64. 2012
    ..We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic properties of MLN8237...
  23. pmc Cutting edge: Lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin
    Ichiko Kinjyo
    Abramson Family Cancer Research Institute, Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 185:7151-5. 2010
    ..Thus, antagonism of Eomes emerges as a therapeutic target for DN T cell ablation in ALPS...
  24. ncbi Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, ARC 902, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
    Blood 105:2443-8. 2005
    ..Our data further suggest that a number of patients with ES may have ALPS, a novel finding with important therapeutic implications...
  25. ncbi Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis
    Naomi J Balamuth
    Department of Pediatrics, Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Pediatr Hematol Oncol 29:569-73. 2007
    ..This patient demonstrated a rapid clinical response and an 18-fold reduction in EBV viral load within 24 hours of receiving rituximab. He remains free of disease 8 months after completing treatment...